Cenobamate: real-world data from a retrospective multicenter study.
Stephan LauxmannDavid HeuerJan HeckelmannFlorian P FischerMelanie SchreiberElisabeth SchriewerGuido WidmanYvonne WeberHolger LercheMichael AlberSigrid Schuh-HoferStefan WolkingPublished in: Journal of neurology (2024)
CNB proved to be a highly effective and generally well-tolerated ASM in patients with severe drug-resistant epilepsy, comprising a broad array of epilepsy syndromes beyond focal epilepsy.